Search results for "Italy"

showing 10 items of 2893 documents

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SR…

OncologyMaleAnatomy and PhysiologyBone diseaseEpidemiologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentMetastasisMetastasisbone metastasesRenal cell carcinomaBasic Cancer ResearchMedicineMusculoskeletal SystemMultidisciplinaryDiphosphonatesrenal cell carcinoma bone metastasis zoledronic acidQRBone metastasisKidney NeoplasmsOncologyItalyObservational StudiesDisease ProgressionMedicineFemaleCancer Epidemiologymedicine.drugResearch Articlemedicine.medical_specialtyClinical Research DesignSciencerenal cancerBone NeoplasmsInternal medicineHumansBonerenal cancer; bone metastasesRetrospective Studiesbusiness.industryRenal Cell CarcinomaCancerCancers and NeoplasmsBone fracturemedicine.diseaseSurgeryRadiation therapyGenitourinary Tract TumorsZoledronic acidbusiness
researchProduct

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyur…

1996

BACKGROUND To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea. METHODS A total of 70 patients fulfilling the standard eligibility for a Phase II study were enrolled in the trial. Forty patients had advanced pancreatic adenocarcinoma and 30 had advanced gallbladder carcinoma. The treatment sched…

OncologyMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticPancreatic diseaseAntidotesLeucovorinPhases of clinical researchAdministration OralAntineoplastic AgentsAdenocarcinomaGastroenterologyDrug Administration ScheduleMetastatic carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaInfusions IntravenousAgedbusiness.industryGallbladderCarcinomaRemission InductionLeukopeniaMiddle Agedmedicine.diseasePancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyTolerabilityItalyInjections IntravenousDisease ProgressionAdenocarcinomaFemaleGallbladder NeoplasmsFluorouracilbusinessProgressive diseaseCancer
researchProduct

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

2009

The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relap…

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsRisk factors MYCNNeuroblastomaSurvival relapse progressionRisk FactorsNeuroblastomaInternal medicinemedicineHumansStage (cooking)Risk factorChildSurvival analysisRetrospective StudiesSalvage Therapybusiness.industryCancerInfantRetrospective cohort studymedicine.diseaseSurvival AnalysisConfidence intervalOncologyItalyChild PreschoolCohortDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessChildhood cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases and risk factors for recurrence in a high prevalence of goiter area

2010

BACKGROUND. Papillary thyroid microcarcinoma (PTMC) is diagnosed with increasing frequency. Since risk factors for an aggressive clinical behavior have not been clearly delineated, the best therapeutic option and follow up protocol for PTMC have not been established yet, especially in case of incidental diagnosis after partial thyroidectomy for benign disease. We reviewed our series of patients with PMTC to determine risk factors for recurrence in a high prevalence of goiter area. METHODS. The medical records of all the patients who underwent total thyroidectomy (TT) with a final pathology report of PTMC between October 2002 and June 2007 were reviewed. Demographic, clinical and pathologica…

OncologyMaleGoiterendocrine system diseasesmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEPapillaryPapillary thyroid cancerRisk Factors80 and overPrevalenceMedicineChildLymph nodeThyroid cancerAged 80 and overGoiterThyroidMiddle AgedPrognosismicrocarcinoma thyroid.medicine.anatomical_structureLocalItalyLymphatic MetastasisThyroidectomyFemaleRadiologyAdultendocrine systemmedicine.medical_specialtyAdolescentInternal medicineCarcinomaHumansNeoplasm InvasivenessThyroid NeoplasmsAgedCompletion thyroidectomyChi-Square Distributionbusiness.industryAdolescent; Adult; Aged; Aged; 80 and over; Carcinoma; Papillary; Chi-Square Distribution; Child; Female; Goiter; Humans; Italy; Linear Models; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence; Local; Prevalence; Prognosis; Risk Factors; Thyroid Neoplasms; ThyroidectomyCarcinomaThyroidectomymedicine.diseaseCarcinoma PapillaryNeoplasm RecurrenceLinear ModelsLymph Node ExcisionSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study

2018

Background and Purpose: Approximately 20% of melanoma patients harbor metastases in non-sentinel nodes (NSNs) after a positive sentinel node biopsy (SNB), and recent evidence questions the therapeutic benefit of completion lymph node dissection (CLND). We built a nomogram for prediction of NSN status in melanoma patients with positive SNB. Methods: Data on anthropometric and clinicopathological features of patients with cutaneous melanoma who underwent CLND after a positive SNB were collected from nine Italian centers. Multivariate logistic regression was utilized to identify predictors of NSN status in a training set, while model efficiency was validated in a validation set. Results: Data …

OncologyMaleSkin NeoplasmsSettore MED/19 - Chirurgia PlasticaLogistic regressionSurgery; Oncology; Sentinel Node Biopsy; Melanoma0302 clinical medicineRisk FactorsMedicine030212 general & internal medicineLymph nodeMelanomaSurgery Oncology lymphnodes melanoma metastasis dissection biomarkerslymphnodesMelanomaTorsoSentinel nodeMiddle AgedTumor Burdenmedicine.anatomical_structuredissectionItalyOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisArea Under CurveLymphatic MetastasisSurgery; OncologyFemalemedicine.medical_specialtyNO03 medical and health sciencesSentinel Node BiopsyInternal medicinemetastasisHumansAgedRetrospective StudiesReceiver operating characteristicbusiness.industrySentinel Lymph Node BiopsybiomarkersExtremitiesNomogrammedicine.diseaseConfidence intervalNomogramsROC CurveCutaneous melanomaLymph Node ExcisionSurgeryLymph Nodesbusiness
researchProduct

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

2021

Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-u…

OncologyMaleSurvivalHepatocellular carcinomaCohort study Hepatocellular carcinoma Prognosis Sorafenib SurvivalSeverity of Illness IndexAntineoplastic Agent0302 clinical medicineProspective StudiesLiver NeoplasmsGastroenterologyMiddle AgedSorafenibPrognosisTreatment OutcomeItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleLiver cancerCohort studymedicine.drugCohort studySorafenibCohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; Survivalmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIAAntineoplastic AgentsRisk Assessment03 medical and health sciencesInternal medicinemedicineHumansneoplasmsPrognostic modelsNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGold standardmedicine.diseasedigestive system diseasesMulticenter studybusiness
researchProduct

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

OncologyMaleTime FactorsDatabases FactualCancer Treatmentlcsh:MedicinePredictive Value of TestPediatricsBiochemistryGeographical locationsNeoplasms Multiple PrimaryDecision Support Technique0302 clinical medicineInterquartile rangeRetrospective StudieMultiple PrimaryRisk FactorsNeoplasmsMedicine and Health SciencesEthnicitiesPublic and Occupational HealthLiver DiseasesLiver NeoplasmsChild HealthGeneral MedicineMiddle AgedPrognosisItalian PeopleTumor BurdenQuartileOncologyCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisPredictive value of testsCohortPerspectiveHong Kong030211 gastroenterology & hepatologyFemaleSurvival Analysialpha-FetoproteinsHumanBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularAsiaTime FactorSettore MED/12 - GASTROENTEROLOGIAAged; Carcinoma Hepatocellular; Databases Factual; Decision Support Techniques; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms Multiple Primary; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Taiwan; Time Factors; Tumor Burden; alpha-Fetoproteins; Biotechnology; Biochemistry; Molecular Biology; Cell BiologyTaiwanReproducibility of ResultGastroenterology and HepatologyCarcinomasRisk AssessmentDecision Support Techniques03 medical and health sciencesDatabasesDiagnostic MedicinePredictive Value of TestsInternal medicineGastrointestinal TumorsmedicineHumansNeoplasm Invasivenessalpha-FetoproteinMolecular BiologySurvival analysisFactualAgedNeoplasm StagingRetrospective StudiesNeoplasm InvasivenePerformance statusbusiness.industryRisk Factorlcsh:RCarcinomaCancers and NeoplasmsReproducibility of ResultsRetrospective cohort studyHepatocellularHepatocellular CarcinomaCell BiologySurvival AnalysisBCLC StageSurgeryPeople and PlacesPopulation Groupingsbusiness
researchProduct